Kerry Atkinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kerry Atkinson has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Gary Brooke
2 shared publicationsNina Ilic
Mater Health Services, Brisbane, Queensland, 4101, Australia
2 shared publications- Rebecca Pelekanos
University of Queensland Centre for Clinical Research, Herston, Brisbane, Queensland, Australia
2 shared publications Sonia Hancock
2 shared publicationsTony Rossetti
2 shared publications- Celena Heazlewood
Mater Medical Research Institute
1 shared publication
Latest Publications
- Open Access
- 7 March 2012
- Published by IntechOpen
Exploring the Human Term Placenta as a Novel Source for Stem Cells and their Application in the Clinic
- 7 March 2012
- Published by IntechOpen
Open AccessExploring the Human Term Placenta as a Novel Source for Stem Cells and their Application in the Clinic
- 11 February 2011
- Published by Springer Nature
- Vol. 698, 89-106
Manufacture of Clinical Grade Human Placenta-Derived Multipotent Mesenchymal Stromal Cells
Clinical grade human mesenchymal stem cells (MSC) are manufactured and used in clinical trials for a range of regenerative and inflammatory diseases. Human MSC have now been derived from tissues other than bone marrow, such as placenta, as described in this laboratory protocol. It provides instructions for clinical grade MSC manufacturing according to the Code of Good Manufacturing Practice (cGMP) principles and according to policies and procedures of our internal Quality Management System (QMS), which is based on the International Organization for Standardization (ISO) standard requirements. Relevant organizational structure and QMS elements are presented.
- 11 February 2011
- Published by Springer Nature
- Vol. 698, 89-106
Manufacture of Clinical Grade Human Placenta-Derived Multipotent Mesenchymal Stromal Cells
Clinical grade human mesenchymal stem cells (MSC) are manufactured and used in clinical trials for a range of regenerative and inflammatory diseases. Human MSC have now been derived from tissues other than bone marrow, such as placenta, as described in this laboratory protocol. It provides instructions for clinical grade MSC manufacturing according to the Code of Good Manufacturing Practice (cGMP) principles and according to policies and procedures of our internal Quality Management System (QMS), which is based on the International Organization for Standardization (ISO) standard requirements. Relevant organizational structure and QMS elements are presented.
- Open Access
- 29 March 2009
- Published by Hindawi Limited in International Journal of Cell Biology
- Vol. 2009, 1-11
Cellular Therapy for Repair of Cardiac Damage after Acute Myocardial Infarction
Cardiovascular diseases, particularly acute myocardial infarction, are the leading causes of death worldwide. Important advances have been made in the secondary treatment for cardiovascular diseases such as heart transplantation and medical and surgical therapies. Although these therapies alleviate symptoms, and may even improve survival, none can reverse the disease process and directly repair the lasting damage. Thus, the cure of cardiovascular diseases remains a major unmet medical need. Recently, cellular therapy has been proposed as a candidate treatment for this. Many stem and progenitor cell populations have each been suggested as a potential basis for such therapy. This review assesses some of the more notable exogenous adult cell candidates and provides insights into the mechanisms by which they may mediate improvement in cardiac function following acute myocardial infarction. Research into the cellular therapy field is of great importance for the further planning of clinical trials for cardiac cellular myoplasty.
- 29 March 2009
- Published by Hindawi Limited in International Journal of Cell Biology
- Vol. 2009, 1-11
Open AccessCellular Therapy for Repair of Cardiac Damage after Acute Myocardial Infarction
Cardiovascular diseases, particularly acute myocardial infarction, are the leading causes of death worldwide. Important advances have been made in the secondary treatment for cardiovascular diseases such as heart transplantation and medical and surgical therapies. Although these therapies alleviate symptoms, and may even improve survival, none can reverse the disease process and directly repair the lasting damage. Thus, the cure of cardiovascular diseases remains a major unmet medical need. Recently, cellular therapy has been proposed as a candidate treatment for this. Many stem and progenitor cell populations have each been suggested as a potential basis for such therapy. This review assesses some of the more notable exogenous adult cell candidates and provides insights into the mechanisms by which they may mediate improvement in cardiac function following acute myocardial infarction. Research into the cellular therapy field is of great importance for the further planning of clinical trials for cardiac cellular myoplasty.
- 21 January 2009
- Published by Wiley in British Journal of Haematology
- Vol. 144 (4) , 571-579
Manufacturing of human placenta‐derived mesenchymal stem cells for clinical trials
Summary: Mesenchymal stem cells (MSC) are being used increasingly in clinical trials for a range of regenerative and inflammatory diseases. Bone marrow is the traditional source but is relatively inaccessible in large volume. MSC have now been derived from tissues other than bone marrow including placenta and adipose tissue. We have used placenta obtained after delivery as a source of MSC and have been unable to detect any marked differences from marrow‐derived MSC in terms of cell surface phenotype, chemokine receptor display, mesodermal differentiation capacity or immunosuppressive ability. This report described our manufacturing process for isolating and expanding placenta‐derived human MSC and their safe infusion into the first patient in a clinical trial program of human placenta‐derived MSC.
- 21 January 2009
- Published by Wiley in British Journal of Haematology
- Vol. 144 (4) , 571-579
Manufacturing of human placenta‐derived mesenchymal stem cells for clinical trials
Summary: Mesenchymal stem cells (MSC) are being used increasingly in clinical trials for a range of regenerative and inflammatory diseases. Bone marrow is the traditional source but is relatively inaccessible in large volume. MSC have now been derived from tissues other than bone marrow including placenta and adipose tissue. We have used placenta obtained after delivery as a source of MSC and have been unable to detect any marked differences from marrow‐derived MSC in terms of cell surface phenotype, chemokine receptor display, mesodermal differentiation capacity or immunosuppressive ability. This report described our manufacturing process for isolating and expanding placenta‐derived human MSC and their safe infusion into the first patient in a clinical trial program of human placenta‐derived MSC.